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We have identified a population of T lymphocytes in peripheral blood, Vδ1 TCRγδ T lym-
phocytes, which unexpectedly was uniquely expressing high production of interferon-γ 
in newly diagnosed, untreated multiple sclerosis (MS) patients. IFN-γ production in this 
population distinctly correlated to parameters of clinical disease activity, inflammation, 
and neuronal damage. These Vδ1 T lymphocytes belong to a population of innate T lym-
phocytes that recognize antigen in the context of CD1d/CD1c and which include reactivity 
to the myelin glycosphingolipid sulfatide. Importantly, patients treated with natalizumab, 
blocking leukocyte transmigration to central nervous system, had completely normalized 
levels of interferon-γ-producing Vδ1 T lymphocytes. A biomarker and early sign of demy-
elinating disease in MS is much warranted and would help identify immunopathogenesis 
and prognosis of disease as well as monitor success with adequate treatment. The 
present study identifies the Vδ1 T lymphocytes as an early marker of MS and a possible 
link to understanding the disease etiology.
Keywords: cerebrospinal fluid, gamma-delta T cells, interferon-gamma, multiple sclerosis, natalizumab, Vdelta1 
T cells
inTrODUcTiOn
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) where 
the myelin sheath around nerve fibers becomes the target of an autoimmune attack. This leads to 
demyelination, axonal loss, and subsequent progressive neurologic functional deficits (1). In a major-
ity of patients, the initial phase of the disease is characterized by relapsing–remitting MS (RRMS), 
periods of exacerbation of neurological symptoms followed by substantial remission that can last 
for months and sometimes several years. The underlying mechanisms involved in the initiation of 
Abbreviations: CSF, cerebrospinal fluid; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic 
protein; HDs, healthy donors; iNKT, invariant natural killer T; MAIT, mucosal-associated invariant T; MS, multiple sclerosis; 
new-MS, newly diagnosed MS patients; NFL, neurofilament light chain; NTZ, natalizumab.
Table 1 | Demographic and clinical features of newly diagnosed multiple 
sclerosis (new-Ms) patients and healthy controls.
new-Ms patients (n = 36) healthy donors (control) 
(n = 59)
age, years
Range 18–62 20–67
Mean ± SEM 35.4 ± 1.4 37.2 ± 1.6
gender, number (%)
Male 10 (27.7) 23 (39.0)
Female 26 (72.2) 36 (61.0)
Mri T1 gd+ lesions, number
Range 0–15 NA
Mean ± SEM 2.92 ± 0.61 NA
Mri T2 lesions, number
Range 2–20 NA
Mean ± SEM 12.41 ± 1.10 NA
eDss
Range 0–6 NA
Mean ± SEM 2.14 ± 0.19 NA
csF igg index
Range 0.44–3.09 NA
Mean ± SEM 1.20 ± 0.15 NA
csF Ocb, number
Present 35 NA
Absent 1 NA
CSF, cerebrospinal fluid; EDSS, expanded disability status scale; Gd+, gadolinium 
contrast enhancing; MRI, magnetic resonance imaging; NA, not applicable; OCB, 
oligoclonal bands.
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disease and the processes that are responsible for the progres-
sion to chronic autoimmunity are poorly understood. Although 
geographical distribution, lifestyle, and environmental factors 
may be contributing in MS, extensive investigations including 
genetic association studies in animal models and MS patients 
support a primary role for cell-mediated immune mechanisms 
in the disease pathogenesis (1).
A pathogenic role for CD4+ Th cells is well established in MS, 
but the specific contribution of different Th subsets to the disease 
process has remained elusive. Early studies indicated a primary 
pathogenic role for IFN-γ-producing Th1  cells, however, this 
view has been challenged in recent years when IL-17-producing 
Th17 cells have been viewed as the main actors in the course of MS. 
The current notion is that a mix of Th1/Th17 cells and associated 
proinflammatory cytokines act in concert to precipitate disease, 
and that the production of combinations of IL-17, IFN-γ, and 
granulocyte-macrophage colony-stimulating factor characterize 
pathogenic Th cells (2–7). By contrast, IL-10-producing Th cells 
are considered to be protective.
γδ cells express a distinct TCR composed of the TCR γ- and 
δ-chains (8). They represent a group of cells called innate-like 
lymphocytes characterized by rapid activation and early involve-
ment during immune responses. γδ cells are suggested to play a 
role in both MS and the murine model for the disease, experi-
mental autoimmune encephalomyelitis (EAE) (9–11). Clonally 
expanded γδ cells have been found accumulated in acute, demy-
elinating MS brain lesions (12) and in cerebrospinal fluid (CSF) 
from recent-onset MS patients (13), strongly indicating that γδ 
cells are involved in MS pathogenesis. γδ cells are particularly 
abundant in peripheral tissues, most notably, the skin and intes-
tinal epithelium where they monitor early signs of tissue infection 
and stress. Human γδ cells are dominated by two main popula-
tions defined by their expression of the Vδ1 or Vδ2 segments of 
the TCR δ-chain. The Vδ1 and Vδ2 T cells predominate in the 
mucosal epithelium and circulation, respectively.
In general, the immunobiology of Vδ1 T  cells is less well 
understood than that of the Vδ2 cells. However, recent findings 
shed new light on the ligand recognition by the Vδ1 TCR. It 
was demonstrated that the glycosphingolipid antigen sulfatide 
presented on the major histocompatibility complex (MHC) 
class I-like CD1d and CD1c molecules was recognized by Vδ1 
cells (14–16). The myelin sheath, the target of the autoimmune 
attack in MS/EAE, is a rich source of sulfatide. This suggests that 
CD1c/d-restricted T cells could be activated by myelin-derived 
sulfatide in MS and, thereby, could be implicated in the onset of 
MS disease. Indeed, sulfatide reactive T  cells have been found 
to be more frequent in the peripheral blood of MS patients than 
in healthy individuals (17), and studies in the mouse model 
demonstrated that sulfatide reactive CD1d-restricted T  cells 
accumulated in the CNS during EAE (18). Taken together, these 
data indicate that Vδ1 cells, which include sulfatide reactive cells, 
may be involved in MS disease.
Here, we have investigated Vδ1 cells for their activation state 
and effector cell characteristics and compared them to other 
T cell subsets in newly diagnosed treatment naïve MS patients 
and patients treated with the disease-modifying therapy natali-
zumab (NTZ).
MaTerials anD MeThODs
experimental Design
Newly diagnosed MS patients (new-MS) diagnosed using the 
revised McDonald criteria (19) (n = 36) were enrolled at the MS 
center of Sahlgrenska University Hospital, Gothenburg, Sweden. 
Patients with any other chronic ailment, active disease, or receiv-
ing any disease-modifying treatment at the time of sampling were 
excluded. Treated MS patients (n = 25) receiving 300 mg NTZ 
intravenously once monthly were also included. Some (n =  7) 
new-MS patients were investigated before treatment and after 1–6 
monthly doses of NTZ. Age- and gender-matched healthy blood 
donors (HD; n = 59) who visited the Department of Transfusion 
Medicine, Sahlgrenska University Hospital, served as controls. 
Demographics and clinical features of subjects are shown in 
Table 1.
sample Preparation
Peripheral blood and CSF were always obtained for clinical pur-
poses. The spinal tap and the CSF samples were handled accord-
ing to the consensus protocol of the BioMS-EU network for CSF 
biomarker research in MS (20). Blood samples from patients 
(from patients on NTZ treatment just before the next dose) and 
healthy donors (HDs) were collected in heparinized tubes. Blood 
was diluted to 1:1 with sterile phosphate-buffered saline [(PBS); 
pH 7.2]. PBMCs were isolated by density gradient centrifugation 
using Ficoll-Paque (density: 1.077  g/mL; GE Healthcare). Cell 
viability was determined by Trypan Blue dye exclusion. The CSF 
lymphocyte cellularity was 9,850 ± 1,986/mL.
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Flow cytometry
Immunophenotyping of cells was performed using 14-color 
flow cytometry. The following fluorochrome-conjugated anti-
human monoclonal antibodies (mAbs) were used: anti-CD4 
(clone OKT4), anti-CD8a (RPA-T8), anti-CD161 (HP-3G10), 
anti-TCRγδ (B1), anti-CCR4 (D8SEE) (all purchased from 
eBioscience), anti-CD3ϵ (OKT3), anti-CD19 (HIB19), anti-
CD27 (O323), anti-CD28 (CD28.2), anti-CD45RA (HI100), 
anti-CD45RO (UCHL1), anti-CD49d (9F10), anti-CD69 (FN50), 
anti-TCRγδ (B1), anti-TCR Vα7.2 (3C10), anti-CCR6 (G034E3), 
anti-CCR7 (G043H7), anti-CXCR3 (G025H7) (all purchased 
from BioLegend), and anti-TCR Vδ1 (TS8.2) (Thermo Fisher 
Scientific). PBS-57 (an analog of α-galactosylceramide)-loaded 
and unloaded human CD1d tetramers were kindly provided by 
National Institutes of Health Tetramer Core Facility. Cells were 
stained with CD1d tetramers for 45  min at room temperature 
and then with surface mAbs for 30 min at 4°C. Cells were always 
stained with LIVE/DEAD® aqua stain (Life Technologies) and Fc 
receptor binding inhibitor (eBioscience). Staining with the anti-
TCRγδ (B1) mAb results in the appearance of two TCRγδ cell 
populations when plotted against CD3 or Vδ1 as noted before 
(21).
To stain intracellular cytokines and granzyme-B (GrB), PBMCs 
were stimulated with PMA (50 ng/mL) and ionomycin (500 ng/
mL) (Sigma-Aldrich) in the presence of Brefeldin A (eBioscience) 
for 4  h at 37°C. Cells were surface stained as described above, 
fixed, and permeabilized using intracellular fixation and per-
meabilization buffer (eBioscience), and stained with anti-IFN-γ 
(4S.B3), anti-IL-10 (JES3-9D7), anti-IL-17A (BL168), anti-GrB 
(GB11) mAbs (BioLegend), and anti-TNF-α (MAb11) (eBiosci-
ence). Fluorescence minus one was used as background control 
(Figure S1A in Supplementary Material). Transcription factors 
were stained ex vivo with anti-T-bet (4B10) (BioLegend) and 
anti-RORγt (AFKJS-9) mAbs using Foxp3 staining buffer (eBio-
science). Data were acquired using an LSRII (BD Biosciences) 
cytometer, and analyzed using FlowJo v.10 software (Tree Star).
neurofilament light chain (nFl) and glial 
Fibrillary acidic Protein (gFaP) analyses
Neurofilament light chain concentration in CSF was measured 
with a sensitive sandwich enzyme-linked immunosorbent assay 
(ELISA) (NF-light® ELISA kit, UmanDiagnostics AB, Umeå, 
Sweden). Intra- and inter-assay coefficients of variation were 
below 10%. The lower limit of quantification of the assay was 
31 pg/mL. The GFAP concentration was measured by ELISA, as 
previously described (22). The absorbance was read at 490 nm, 
and the sensitivity of the GFAP assay was 16 pg/mL. Both assays 
were conducted at the Clinical Neurochemistry Laboratory 
(Sahlgrenska University Hospital) according to protocols 
approved by the Swedish Board for Accreditation and Conformity 
Assessment.
Magnetic resonance imaging (Mri)
Diagnostic MRI scans of brain and cervical column were per-
formed with 3.0-T machine using 1–3 mm thickness according to 
the Swedish guidelines (23). A standard protocol for MS was used 
with T1 3D-weighted sequence following a dose of intravenous 
gadolinium contrast, T2-weighted sequence, and 3D fluid-
attenuated inversion recovery sequence. In all patients included 
in the study, the MRI demonstrated dissemination of lesions in 
space and time, thus fulfilling the revised McDonald criteria for 
MS diagnosis (19).
statistical analysis
A Gaussian distribution was first assessed using D’Agostino and 
Pearson omnibus normality test, and parametric or non-para-
metric tests were carried out using unpaired t-test with Welch’s 
correction or Mann–Whitney U-test (two-tailed) for unpaired 
data and paired t-test or Wilcoxon matched-pairs signed rank test 
(two-tailed) for paired data to assess the differences between two 
groups, as specified in the figure legends. Correlation analyses 
were performed using Spearman’s non-parametric correlation. 
Results are presented as mean ± SEM, and P-values <0.05 were 
considered to be statistically significant. All statistical tests were 
performed using Prism GraphPad Software, version 6 (La Jolla, 
CA, USA).
study approval
The Regional Ethical Review Board in Gothenburg, Sweden, 
approved this study, and written informed consent was obtained 
from each study subject.
resUlTs
The Tcr Vδ1 subset in csF of new-Ms 
Patients
We first determined the frequencies of Vδ1 cells and differ-
ent innate-like and conventional T  lymphocyte populations 
(Figure 1A) in freshly provided CSF and PBMC from new-MS 
and PBMC from HD. It is important to note that none of the new-
MS patients had received any treatment for MS disease, excluding 
prior immunomodulatory effects due to such treatment. We 
observed a wide range of γδ cell frequencies in PBMC of both 
new-MS and HD, without significant differences between the 
groups (Figure 1B). In new-MS patients, CSF had slightly lower 
frequencies than PBMC of total γδ cells among CD3+ cells. The 
size of the Vδ1 T subset among CD3+ cells in PBMC from new-
MS patients did not show a significant difference compared with 
HD, while the frequency of Vδ1 cells among γδ cells was slightly 
increased in new-MS PBMC compared to HD PBMC. In new-MS 
individuals, the proportion of the Vδ1 cell subset was the same 
in CSF as in PBMC, suggesting that Vδ1 cells may enter the CNS 
in MS, in accordance with previous studies (13). Thus, we found 
that Vδ1 cells were present in CSF from new-MS patients, at the 
same levels as those found in MS PBMC.
We analyzed two additional subsets of innate-like T lympho-
cytes, mucosal-associated invariant T (MAIT) cells, and invariant 
natural killer T (iNKT) cells, which have been implicated in MS 
and EAE (24, 25). MAIT  cells are activated by microbial and 
endogenous vitamin B metabolites presented on the MHC class 
I-like molecule MR1 and are defined by high expression of CD161 
and an invariant TCR Vα7.2. The frequency of MAIT cells was 
FigUre 1 | increased Tcr Vδ1 T cell subset among γδ cells in newly diagnosed multiple sclerosis (new-Ms) patients. (a) Representative flow cytometric 
dot plots of healthy donors (HDs) PBMC showing gating strategy to define different T cell populations. TCR γδ+ T cells were first gated among CD19−CD3+ T cells 
(upper left and middle plots) and subdivided into Vδ1+ (Vδ1) and Vδ1− (Vδ1−) T cells (lower left plot). After that, mucosal-associated invariant T (MAIT) cells were 
gated out from the TCR γδ− CD3+ population (upper right plot), and thereafter CD4, CD8, and αGalCer-loaded CD1d-tetramer (CD1d-tet αGalCer) positive cells 
[invariant natural killer T (iNKT) cells] were gated among the remaining cells (lower row, middle and right plots). (b) Total TCRγδ cells were determined among 
CD3+CD19− cells (referred to as CD3+ cells) (left), and TCR Vδ1 cells were represented among CD3+ cells (middle) and among TCRγδ+ cells (right). (c) Frequency of 
MAIT cells among αβT (CD3+CD19− TCRγδ−) cells. (D) Frequencies of CD4, CD8, and iNKT cells within the CD3+CD19−TCRγδ−MAIT− population (referred as αβT 
MAIT− cells). Bars represent mean ± SEM (HD, n = 55; new-MS, n = 34). *P < 0.05; **P < 0.01; ****P < 0.0001. Unpaired t-test with Welch’s correction or 
Mann–Whitney U-test (two-tailed) between HD and new-MS and paired t-test or Wilcoxon matched-pairs signed rank test (two-tailed) between blood and 
cerebrospinal fluid (CSF) samples from new-MS were used to assess significance.
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similar in PBMC from new-MS and HD, but was several fold 
lower in new-MS CSF (Figure 1C), in agreement with a recent 
study (26). iNKT cells are α-galactosylceramide (αGalCer) reac-
tive, CD1d-restricted TCRαβ cells that use an invariant Vα24 
TCR α-chain. Employing αGalCer-loaded CD1d-tetramers, we 
observed that frequencies of iNKT cells in PBMC from new-MS 
patients and HD were similar, while they were significantly lower 
in new-MS CSF (Figure 1D). Finally, among conventional T cells, 
the proportion of CD4 T cells was comparable in HD and new-MS 
PBMC and CSF, while CD8 T cells were slightly lower in new-MS 
CSF than in PBMC (Figure 1D).
Thus, in MS patients, Vδ1 T  cells were present in CSF at 
frequencies equal to PBMC, while the two other innate-like 
T cell populations, MAIT, and iNKT cells, had severely reduced 
representation in CSF.
Vδ1 cells from new-Ms Patient csF had 
an altered Phenotype
We next investigated the expression of surface markers that could 
identify T  cells engaged in immune responses in MS patients 
(Figure 2). Cells were stained for CD69, first defined as an early 
activation marker but also expressed on leukocytes at the site of 
inflammation, the late activation/memory marker CD45RO, and 
CD161, a receptor with co-regulatory function and associated 
with IL-17 production (27). CD161 is found on NK  cells and 
subpopulations of T cells, such as MAIT cells and the majority 
of γδ T  cells expressing the Vδ2 TCR. Throughout, we have 
compared Vδ1+ T cells (Vδ1 T) with the rest of γδ T cells (here 
termed Vδ1− T cells), and with the other T cell subsets. Peripheral 
blood γδ T cells predominantly use the Vδ2 TCR-chain, thus the 
majority of γδ T cells here defined as Vδ1− are likely to express 
the Vδ2 segment (28, 29). iNKT cells were omitted from these 
analyses due to limiting cell numbers in several samples.
All T  cell populations, including γδ T  cell subsets, dem-
onstrated an increased proportion of CD69+ cells in CSF (an 
average of 15–30% in the different cell populations) compared 
to PBMC (average of 7% or less) from new-MS patients, indicat-
ing a memory/tissue resident T cell phenotype (Figures 2A,B). 
Moreover, CD161 levels were reduced on both γδ cell subsets in 
CSF, in particular on Vδ1 T cells, while CD161 instead was found 
on a higher proportion of CSF CD4+ T cells (Figures 2A,B). This 
further illustrates that these cells might be functionally altered.
Besides a minor reduction in CD45RO expression among 
Vδ1− T cells in new-MS PBMC, no alterations in the expression 
of the analyzed surface markers by γδ T cell subsets were found 
between new-MS and HD PBMC. CD45RO was also slightly 
lower in frequency in new-MS CD4 T  cells than in HD CD4 
T cells, and CD8 T cells from patients had fewer cells expressing 
CD161 than CD8 cells from HD (Figure 2B).
We finally tested an additional pair of surface markers, CD27, 
and CD45RA, hoping to distinguish activated γδ cells in PBMC 
of MS patients. It has been proposed that γδ cells can be divided 
into different naïve/memory/effector subsets by their differential 
expression of these markers (30). Accordingly, γδ cells were 
divided into subsets as shown in Figure 2C. The expression of 
these markers by Vδ1 and Vδ1− T cells in PBMC did not differ 
markedly between HD and new-MS patients. In both groups, 
Vδ1 cells were comprised primarily of cells with phenotypes of 
naïve and terminally differentiated cells, while Vδ1− cells had 
mostly naïve and central memory phenotypes (Figures 2C,D).
Taken together, the analysis of a set of activation/memory 
markers demonstrated that all T  cell subsets in CSF contained 
elevated frequencies of recently activated cells with potentially 
altered function compared to PBMC, consistent with an active 
involvement in CNS autoimmunity. By contrast, neither of these 
markers revealed an increase in activated T cells in the peripheral 
blood of new-MS patients, with the exception of minor changes 
found in CD4 and CD8 T cells.
iFn-γ Production Was significantly 
increased specifically in Vδ1 cells in new-
Ms Patients
Having failed to find marked differences in activation markers 
on peripheral blood T cells from MS patients compared to HD, 
we turned to a wide analysis of putative function (Figure  3). 
Strikingly, we demonstrate a significant increase in IFN-γ 
production in Vδ1 cells from new-MS patients compared to 
those from HD (39.1 versus 22.9%, P =  0.0079) (Figure  3A). 
A high proportion of Vδ1 T cells also produced TNF-α and GrB 
(Figure  3A), and the Vδ1 population displayed high levels of 
T-bet, a transcription factor associated with IFN-γ production 
(Figure  3B). In fact, the vast majority of Vδ1 cells producing 
IFN-γ also produced TNF-α, while there were both single and 
double producers of GrB and IFN-γ (data not shown). The 
increased IFN-γ production in new-MS patients was specific for 
Vδ1 cells, as other T cell populations did not exhibit differences 
in the production of IFN-γ (Figure 3A). The production of both 
IL-10 and IL-17A was very low in all T cell subsets from both HD 
and new-MS patients (Figure 3A). CCR6, known to be expressed 
on Th17 cells, was reduced to very low levels on Vδ1 cells in new-
MS PBMC, consistent with negligible levels of IL-17, low RORγt, 
and an elevated IFN-γ expression. By contrast, the percentage 
of Vδ1 cells that expressed CXCR3, CCR4, and CCR7 remained 
unaltered (Figure 3C). Our results clearly demonstrate that, in 
peripheral blood of new-MS patients, Vδ1 cells selectively had a 
significantly elevated capacity to produce IFN-γ.
Previous studies comparing the cytokine profile of γδ T cell 
subsets in HD suggest that Vδ2 cells are more inflammatory 
(produce more IFN-γ and IL-17) while Vδ1 cells are more regula-
tory (produce more IL-10) (31, 32). This was verified by our data 
and is illustrated in Figures S1B,C in Supplementary Material, 
showing results from HD and new MS-patients from Figure 3 
to allow a direct comparison between Vδ1 and Vδ1− T  cells. 
By contrast, in new-MS patients, the frequencies of Vδ1 cells 
producing IFN-γ and IL-10 were not significant different from 
those of Vδ1− T cells.
Vδ1− cells demonstrated higher frequencies of cells produc-
ing IFN-γ and TNF-α compared to Vδ1 cells, while the levels of 
GrB were similar. T-bet expression was not significantly different 
although Vδ1− T  cells showed a tendency of higher levels. By 
contrast, Vδ1 cells contained significantly higher frequencies 
of IL-10-producing cells, although still at low levels, than the 
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FigUre 2 | continued
FigUre 3 | increased iFn-γ production by Vδ1 cells in PbMc from newly diagnosed multiple sclerosis (new-Ms) patients. T cell subsets were defined 
as in Figure 1 and analyzed by flow cytometry for the expression of cytokines (a), transcription factors (b), and chemokine receptors (c). Cells were stimulated as 
described in Section “Materials and Methods” before staining (a) or were stained for directly ex vivo (b,c). Representative plots are shown for Vδ1 and Vδ1− T cells 
from healthy donors (HDs) and new-MS as indicated (a), Vδ1, Vδ1−, mucosal-associated invariant (MAIT), and conventional CD4/8 T cells from new-MS patients 
(b), and for Vδ1 and Vδ1− T cells from HD (c). Bars represent mean ± SEM of cells expressing IFN-γ (HD n = 35, new-MS n = 21), TNF-α (HD n = 18, new-MS 
n = 13), granzyme-B (GrB) (HD n = 13, new-MS n = 12), IL-10 and IL-17A (HD n = 16, new-MS n = 9), CXCR3 and CCR6 (HD n = 22, new-MS n = 13), CCR4 (HD 
n = 17, new-MS n = 9), CCR7 (HD n = 9, new-MS n = 4), and median fluorescent intensity (MFI) for RORγt and T-bet (HD n = 15, new-MS n = 8). *P < 0.05, 
**P < 0.01. Unpaired t-test with Welch’s correction or Mann–Whitney U-test (two-tailed) was used to assess significance.
FigUre 2 | continued 
Vδ1 cells from newly diagnosed multiple sclerosis (new-Ms) patients had a phenotype of recent activation. (a) T cells were gated as in Figure 1, and 
expression of indicated markers was determined. Representative flow cytometric plots are shown for total γδ cells. (b) Cells within each T cell subset expressing 
CD45RO [upper panel, healthy donors (HDs) n = 50, new-MS patients n = 24], CD69 (middle panel, HD n = 40, new-MS n = 24), and CD161 (lower panel, HD 
n = 50, new-MS n = 24) were determined. (c) Based on the expression of CD45RA and CD27 (representative dot plot for Vδ1 cells from HD), Vδ1 cells were divided 
into naïve (Tnaive, CD45RA+CD27+), central memory (Tcm, CD45RA−CD27+), effector (Teff, CD45RA−CD27−), and terminally differentiated effector (Ttd, 
CD45RA+CD27−) cells (30). Graphs compare values for Vδ1 and Vδ1− T cells in PBMC from HD (n = 10) and new-MS patients (n = 7). (D) Vδ1 and Vδ1− T cells from 
HD (n = 10). Bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Unpaired t-test with Welch’s correction or Mann–Whitney U-test 
(two-tailed) for HD versus new-MS PBMC and paired t-test or Wilcoxon matched-pairs signed rank test (two-tailed) for new-MS PBMC versus cerebrospinal fluid 
(CSF) were used to assess significance.
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Vδ1− T cell subset. Expression of RORγt and IL-17A was very low 
in both γδ cell subsets from HD, but Vδ1− cells had an increased 
fraction of cells expressing CCR6, which is associated with IL-17 
production, as well as a slight increase in CCR4.
Thus, our broad analysis of functional attributes of T  cells 
in new-MS peripheral blood could identify that Vδ1 T  cells 
uniquely had a significantly increased capacity to produce IFN-γ, 
implicating Vδ1 cells in the etiology of MS disease.
FigUre 4 | Frequency of iFn-γ+ Vδ1 cells positively correlated with multiple sclerosis (Ms) disease activity, inflammation, and central nervous 
system (cns) damage in newly diagnosed multiple sclerosis patients. The expression of IFN-γ (as determined in Figure 3) in Vδ1 (left plots) and Vδ1− (right 
plots) T cells was correlated with T1 gadolinium contrast-enhanced (Gd+) MRI lesions (upper plots) and T2 lesions (lower plots) (a) and cerebrospinal fluid 
concentrations of biomarkers for CNS damage (NFL, middle plots, and GFAP, lower plots) (b) (n = 21). r is Spearman’s correlation coefficient. NFL, neurofilament 
light chain; GFAP, glial fibrillary acidic protein; MRI, magnetic resonance imaging. Spearman non-parametric correlation test was used. R2 indicates the Goodness of 
Fit line (calculated using linear regression correlation).
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iFn-γ+ Vδ1 cells in Peripheral blood 
correlated with clinical scores for 
Disease activity, inflammation, and axonal 
Damage in Ms Patients
To further substantiate the link between Vδ1 cells and MS dis-
ease, we extended the analysis to biomarkers of disease activity 
and neuronal damage. We had noted that, although the average 
frequency of IFN-γ-producing Vδ1 cells in PBMC of new-MS 
patients was significantly increased compared to that of HD, 
there was a high variability in the values between individual 
new-MS patients. We hypothesized that this diversity could be 
related to heterogeneity in disease activity in the patient group. 
We, therefore, compared our results with clinical data from 
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gadolinium contrast-enhanced (Gd+) MRI investigations that 
detect active MS, i.e., T1 gadolinium contrast-enhanced (Gd+) 
lesions. The frequency of IFN-γ+ Vδ1 cells from PBMC corre-
lated significantly with the number of T1 Gd+ lesions (P = 0.019, 
Figure 4A, upper graph). We also found a correlation with the 
number of T2 lesions (P =  0.0095, Figure  4A, lower graph). 
Moreover, there was a strong correlation between the percent-
age of IFN-γ+ Vδ1 cells from PBMC with CSF concentrations 
of neurofilament light protein NFL (P  =  0.0028) indicating 
axonal damage. By contrast, there was no significant correlation 
with CSF GFAP (P = 0.24), a marker of astrocyte damage and 
astrogliosis (Figure 4B). No correlation with these parameters 
was observed for Vδ1 cells producing other cytokines nor for 
the production of IFN-γ (or other cytokines) in Vδ1− T cells or 
the other T cell subsets (Figure 4 and data not shown). Thus, the 
level of IFN-γ production in Vδ1 T  cells correlated positively 
with biomarkers of axonal damage and disease activity, and 
taken together, these data suggest that Vδ1 cells may have a 
disease-promoting function in early MS.
Disease-Modifying Treatment normalized 
Vδ1 cell iFn-γ Production
We had access to MS patients who were undergoing treatment 
for the disease and could, therefore, explore in a second context 
the association of Vδ1 T cells and disease activity. MS patients 
treated with the disease-modifying agent NTZ, an antibody 
that blocks α4-integrin required for T lymphocyte entry across 
the blood–brain barrier (1), have a drastically reduced disease 
activity (33). We analyzed whether NTZ treatment had an effect 
on the IFN-γ production by Vδ1 cells by comparing patients 
treated with NTZ (NTZ-MS) with our cohorts (see Figure 3A) 
of new-MS patients and HD (Figure  5). We first established 
that Vδ1 cells, like other T cell subsets, have a high expression 
of α4-integrin (Figure  5A). In new-MS patients, the fraction 
expressing α4-integrin among T cells was variable, and on aver-
age, around 50% among Vδ1 cells. Strikingly, MS patients who 
had been treated with NTZ (NTZ-MS) had completely reduced 
frequencies of IFN-γ-producing Vδ1 cells to a level similar to 
HD. The treatment did not reduce IFN-γ production in any other 
T cell population analyzed, rather, there was an increase in IFN-γ 
production in CD4+ T  cells after treatment (Figure  5B). NTZ 
treatment also reduced the fraction of Vδ1 cells producing TNF-
α, and there was a trend, not significant in our data set, of reduc-
tion of GrB in the Vδ1 cell population (Figure 5C). The group 
of patients in Figure  5B that demonstrated normalized IFN-γ 
production in Vδ1 cells had been treated for various periods 
of time, from 1 to 96 monthly doses (illustrated in Figure 5D). 
Indeed, in individual patients among those who had been tested 
both before and after treatment, a significant reduction of IFN-γ 
production specifically in Vδ1 cells by NTZ treatment could 
be observed (P = 0.037, Figure 5E). By contrast, there was no 
consistent alteration of IFN-γ production in any other T  cell 
subset after treatment. Thus, NTZ treatment of MS patients had 
an effect on IFN-γ production that was exclusive to Vδ1 cells, 
reinforcing the notion that Vδ1 T cells may be pathogenic and 
may promote early MS disease.
DiscUssiOn
The early immune events that lead to the precipitation of RRMS 
are not well understood. To shed more light on the early pro-
cesses of MS disease pathogenesis, here, we have investigated a 
T lymphocyte population, Vδ1 TCRγδ T cells, which belong to 
the innate-like lymphocytes characterized by rapid activation and 
early involvement during immune responses. The results demon-
strate that activation of Th1-like Vδ1 cells correlates with disease 
activity and neuronal destruction early in MS pathogenesis and 
imply that Vδ1 cells may contribute to disease progression by the 
production of the proinflammatory cytokine IFN-γ.
Vδ1 cells were present in the CSF of new-MS patients and had 
an elevated expression of CD69 compared to PBMC. This was not 
unique for Vδ1 cells as CD69 was expressed on all T cell popula-
tions in CSF. CD69 has previously been found together with a 
memory phenotype also on T cells in CSF from individuals that 
have no inflammatory CNS disorders, suggesting that memory 
T cells can enter the CSF in healthy individuals and are involved 
in immune surveillance of the CNS (34). We found no alterations 
in the expression of surface markers by Vδ1 cells in PBMC from 
new-MS patients compared to HD; however, more detailed analy-
sis demonstrated that new-MS patients harbored significantly 
higher frequencies than HD of circulating Vδ1 cells that exhibit 
IFN-γ production, without alterations in the expression of other 
cytokines. Other T cell subsets analyzed did not demonstrate any 
changes in cytokine production at the population level. Initially, 
IFN-γ was considered the key pathogenic cytokine in MS, but its 
role in the disease has been questioned during recent years (1, 35, 
36). However, a number of findings support a disease-promoting 
role for this cytokine. Increased levels of IFN-γ are reported in 
CSF in MS, as well as in the spinal cords of mice with EAE (37), 
and recombinant IFN-γ treatment provoked relapses in RRMS 
patients in a clinical trial (38). In the EAE model, myelin-reactive 
Th1  cells adoptively transferred into mice induced the disease, 
and it was shown that Th1 cells drive a spontaneous MS disease 
model (39, 40). Further, a rapid transformation of Th17 cells into 
IFN-γ producers in the CNS of EAE mice was demonstrated using 
IL-17 fate-reporter mice (41), revealing plasticity of Th17 cells. A 
reconciling model has been put forward that emphasize the role of 
IFN-γ-producing T cells in the early phase of CNS autoimmunity, 
proposing that Th1 cells are required to infiltrate the non-inflamed 
CNS, facilitating the entry of Th17 cells (3). The IFN-γ-producing 
Vδ1 cells that we demonstrate in new-MS patients also produced 
TNF-α and to some extent GrB, but very low levels of IL-10 
and IL-17. Consistent with this, Th1-like cytokine expression 
pattern, new-MS Vδ1 cells (like HD Vδ1 cells) were positive for 
Th1-associated T-bet and CXCR3, but were negative for RORγt 
expressed by Th17 cells. A previous study demonstrated that total 
γδ T cells in CSF have a larger fraction of CD161high CCR6+ cells 
than found in PBMC (42). The fact that we find reduced display 
of CD161 on γδ T cells in new-MS CSF compared to PBMC is 
compatible with the data from Schirmer et  al., as we analyzed 
cells positive for only this marker. Taken together, published data 
provide substantial evidence for a pathogenic role for IFN-γ in 
EAE/MS. The fact that we find an elevation of IFN-γ-producing 
Vδ1 cells in new-MS patient PBMC, therefore, implicate that 
FigUre 5 | natalizumab (nTZ) treatment of multiple sclerosis (Ms) patients normalized iFn-γ production in Vδ1 T cells. (a) Expression of α-4 integrin on 
T cell populations (right) [healthy donors (HDs) n = 13, new-MS n = 9, and NTZ-MS n = 3]. Representative staining on total γδ cells from a new-MS patient (left). 
(b,c) Expression of IFN-γ, TNF-α, and granzyme-B (GrB) in PBMC from HD (IFN-γ n = 35, TNF-α n = 18, and GrB n = 13), new-MS (IFN-γ n = 21, TNF-α, and GrB 
n = 12), and NTZ-MS patients (IFN-γ n = 25, TNF-α n = 12, and GrB n = 15). (D) Frequency of IFN-γ producing Vδ1 cells in HD and new-MS patients (bars), and 
after different numbers of monthly NTZ treatments (1–96 treatments, circles representing individual patients; n = 25). (e) Frequencies of IFN-γ-producing Vδ1 (left) 
and Vδ1− T cells (right) were analyzed before and after NTZ treatments (1–6 doses) of new-MS patients. Statistical difference was assessed between the sample 
taken before treatment and the first sample collected after treatment. Bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Unpaired t-test with Welch’s 
correction or Mann–Whitney U-test (two-tailed) and paired t-test or Wilcoxon matched-pairs signed rank test (two-tailed) were used to assess significance. Note that 
data shown for IFN-γ production in (D,e) (first data point after treatment only) are included in (b), and these data shown in (e) are included in (D,b) [for each patient 
in (e), only the data points before treatment and after the first treatment are included].
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these cells may contribute to disease pathogenesis. Future stud-
ies will be important to further characterize Vδ1 cells in CSF to 
strengthen this notion.
In further support of a causal role of Vδ1 cells in MS disease 
etiology, we found that the frequency of IFN-γ producing Vδ1 
cells demonstrated a high correlation with clinical data and 
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biomarkers of disease activity and axonal damage such as num-
bers of MRI lesions and levels of NFL in CSF. The association 
was particularly strong with NFL, a marker of axonal damage. 
The concentration of NFL is shown to be increased in CSF at 
all stages of MS, it is elevated with the presence of active MRI 
lesions, and the highest concentrations are found during acute 
relapses (43). Importantly, long-term follow-up studies have 
demonstrated that the NFL concentrations found at initial diag-
nosis of MS were predictive of disease severity and advancement 
to secondary progressive disease (44). Thus, our findings suggest 
that the Th1-skewed activation of Vδ1 cells is related to axonal 
damage.
Moreover, we found that treatment with the disease-modifying 
therapy NTZ completely reduced Vδ1 T cell IFN-γ production to 
normal levels. If the effect of NTZ on Vδ1 T cells was solely to 
prevent activated Vδ1 T  cells from entering the CNS, it could 
be anticipated that cytokine production in this subset in PBMC 
would be increased after treatment, due to the accumulation 
of activated cells in the circulation, as found for conventional 
CD4+ T  cells (45) and Figure  5. Instead, NTZ normalized the 
IFN-γ-producing capacity of Vδ1 cells. The reason for the dif-
ferential effects on CD4+ T cells versus Vδ1 T cells is unknown 
and can only be speculated about. One possibility is that NTZ 
treatment results in a lower ability of Vδ1 cells to access their 
site of activation, Alternatively, Vδ1 T cells may have an inferior 
cell intrinsic capacity to maintain IFN-γ production long term 
(months) after stimulation. Either mechanism, or a combination, 
could result in the decreased IFN-γ production by Vδ1 T cells 
in treated patients. It is also possible that unknown indirect 
mechanisms cause the reduction in IFN-γ production by Vδ1 
T cells after treatment. Integrin α4β1, targeted by NTZ in MS, is 
required for T lymphocyte transmigration across the blood–brain 
barrier, and in fact, regulates lymphocyte migration in all organs. 
In addition, α4-integrin is found on the cell surface associated 
with either integrin β1 or β7. Integrin α4β7 is essential for homing 
of T lymphocytes to the gut, and NTZ has, therefore, also been 
used for treatment of Crohn’s disease. It remains to be resolved 
whether the putative site of activation of Vδ1 T  cells is in the 
CNS, or potentially another site, and whether this relates to early 
autoimmune activation in MS pathogenesis.
The most predominant location of Vδ1 cells is in the intestinal 
epithelium where they comprise around 70% of γδ lymphocytes 
(46). Intraepithelial T  lymphocytes maintain tolerance and 
integrity of the epithelial barrier under homeostatic conditions 
and promote immune protection from pathogens. Vδ1 cells that 
express IFN-γ and IL-17 are expanded in the periphery during 
some infections (47–49). Vδ1 cells are also implicated in the 
immune response against cancers (50), and intestinal Vδ1 cells 
were found to be the major source of tumor-promoting IL-17 in 
human colorectal cancer (51). This is in stark contrast to healthy 
individuals, in which Vδ1 cells are described as having more of 
regulatory characteristics and less inflammatory functions com-
pared to Vδ2 γδ cells (31, 32). Interestingly, intestinal Vδ1 cells 
are expanded in celiac disease, and Vδ1 cells with gut-homing 
potential appeared in peripheral blood following gluten challenge 
of celiac patients on gluten-free diet (46, 52). This illustrates the 
diverse functions that can be expressed by γδ cells in different 
immune responses (8) and establishes that Vδ1 cells in new-MS 
patients have a functional phenotype, expressing IFN-γ, but not 
IL-17, clearly distinct from these situations. It also points to a 
possible connection between activated systemic Vδ1 cells and an 
immune trigger at a mucosal site. Evidence is accumulating that 
alterations in the intestinal microflora can mediate an increased 
risk for autoimmune disease, including EAE and MS (1, 53–55). 
It is evident from animal experiments that effects of the gut flora 
on T lymphocytes residing in intestinal mucosal tissues influence 
autoimmune responses in remote tissues. In this perspective, Vδ1 
cells residing in the intestinal epithelium, thus located at the first 
tissue barrier in contact with gut bacteria and being sentinels 
of microbial alterations, should be considered in the interplay 
between microbiota and the immune system leading to autoim-
mune disease such as MS. Our finding that new-MS patients have 
a significant increase in IFN-γ-producing circulating Vδ1 cells 
reinforces this notion.
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